

REVIEW —Current Perspective—

Roles of Prostanoids Revealed From Studies Using Mice Lacking Specific Prostanoid Receptors

Fumitaka Ushikubi^{1,*}, Yukihiro Sugimoto², Atsushi Ichikawa² and Shuh Narumiya³

¹Department of Pharmacology, Asahikawa Medical College, Midorigaoka-Higashi 2-1-1, Asahikawa 078-8510, Japan

²Department of Physiological Chemistry, Faculty of Pharmaceutical Sciences, and ³Department of Pharmacology, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606-8315, Japan

Received May 8, 2000

ABSTRACT—The actions of prostanoids in various physiological and pathophysiological conditions have been being examined using mice lacking different prostanoid receptors. Prostaglandin (PG) I₂ worked not only as a mediator of inflammation but also as an antithrombotic agent. PGF_{2α} was found to be an essential inducer of labor. Several important actions of PGE₂ are exerted via each of the four PGE₂ receptor subtypes: EP₁, EP₂, EP₃ and EP₄. PGE₂ participated in colon carcinogenesis via the EP₁. PGE₂ also participates in ovulation and fertilization and contributes to the control of blood pressure under high-salt intake via the EP₂. PGE₂ worked as a mediator of febrile responses to both endogenous and exogenous pyrogens and as a regulator of bicarbonate secretion induced by acid-stimulation in the duodenum via the EP₃. It regulated the closure of ductus arteriosus and showed bone resorbing action via the EP₄. PGD₂ was found to be a mediator of allergic asthma. These studies have revealed important roles of prostanoids, some of which had not previously been known.

Keywords: Prostanoid, Prostaglandin, Thromboxane, Prostanoid receptor, Knock-out mouse

Prostanoids, the prostaglandins (PGs) and thromboxanes (TXs), are the cyclooxygenase metabolites of arachidonic acids and exert a range of actions in the body. These actions are mediated by their respective receptors expressed in the target cells, which are generally present in the vicinity of prostanoid production. The receptors include the DP, EP, FP, IP and TP receptors for PGD₂, PGE₂, PGF_{2α}, PGI₂ and TXA₂, respectively. Moreover, there are four subtypes of the EPs: EP₁, EP₂, EP₃ and EP₄ (1–4). Recently, mice lacking each type and subtype of the prostanoid receptor have been produced and are being examined to clarify the roles of the prostanoids in various physiological and pathophysiological conditions. In this article, we summarize the roles of the prostanoids revealed by these studies to date.

Roles of PGI₂ in inflammation and thrombosis

Prostanoids are known to be an important mediator of inflammation. At inflammation sites, PGE₂ and PGI₂ syn-

ergize with other inflammatory mediators, such as histamine and bradykinin, to induce an increase in vascular permeability and hyperalgesia (5, 6), although which of these prostaglandins mediates the effects in vivo has not been fully elucidated. While PGI₂ is a potent inhibitor of platelet activation and shows a protective effect on vascular endothelial cells, the roles of PGI₂ in thrombosis and/or atherosclerosis have not been fully determined. To clarify these issues, the gene encoding the IP receptor was disrupted (7). Mice lacking the IP (*IP*^{−/−} mice) showed decreased paw edema compared with wild-type mice when injected with carrageenan. Indomethacin treatment decreased this edema by approx. 50% in wild-type mice, which was comparable to the decrease found in *IP*^{−/−} mice. The role of PGI₂ in inflammatory pain was examined using the acetic acid-induced writhing test. *IP*^{−/−} mice showed markedly decreased responses compared with wild-type mice, and their responses were again comparable to those observed in wild-type mice treated with indomethacin. These results suggest that PGI₂ is the main prostanoid mediating the increase of vascular permeability and generating inflamma-

* To whom correspondence should be addressed.

tory pain, at least in these systems. However, PGE₂ and/or PGD₂ would participate in increased vascular permeability and pain transmission under different inflammatory conditions as has been suggested (1). The anti-thrombotic effect of PGI₂ was examined using a thrombosis model in which vascular endothelial cells were damaged by the topical application of FeCl₃ around the carotid artery. *IP*^{-/-} mice showed a markedly enhanced thrombotic tendency, suggesting an important anti-thrombotic role of PGI₂ in thrombosis following endothelial damage. This may partially explain the anti-atherosclerotic role of PGI₂, because atherosclerotic lesions begin with endothelial damage.

Roles of PGF_{2α} in parturition

PGF_{2α} is known to be a potent constrictor of the uterus and a luteolytic factor (8). However, its role in parturition has not been determined. While female *FP*^{-/-} mice showed a normal estrous cycle, ovulation, fertilization and implantation, they failed to perform parturition due to the absence of labor (9). This failure was observed in homozygous female mice regardless of the paternal genotype. Moreover, fetuses could be rescued by cesarean operation at the expected term and developed normally, indicating that the absence of labor was of maternal origin. Because uterine sensitivity to oxytocin increases markedly at term due to the upregulation of oxytocin receptors in the uterus, oxytocin has been proposed to be a key regulator of parturition (10, 11). In *FP*^{-/-} mice, uterine sensitivity to oxytocin remained low, and expression of oxytocin receptor mRNA did not change at term. On the other hand, parturition is preceded by a decline in plasma concentration of progesterone, leading to an increase in myometrial contractility (12, 13). While the plasma concentration of progesterone decreased progressively at day 19–21 in wild-type mice, it remained at a high level during this period in *FP*^{-/-} mice. These results suggest that failure of parturition in *FP*^{-/-} mice may be derived from persistent production of progesterone. In accordance with this, the ovariectomized *FP*^{-/-} female at term delivered pups alive after 24 h, and uterine expression of oxytocin receptor mRNA was induced within 12 h. These results clearly showed that PGF_{2α} works upstream of oxytocin to induce luteolysis and that its uterotonic action in myometrium is not essential for parturition.

Role of PGE₂ in closure of ductus arteriosus and bone resorption

More than 95% of *EP*₄^{-/-} neonates became pale and lethargic approx. 24 h after birth and died within 72 h (14, 15). Histological examination of dying *EP*₄^{-/-} neonates showed marked congestion in the pulmonary capillaries and disorganized and collapsed alveolar structures, suggesting left-sided heart failure. Further examination

revealed patent ductus arteriosus in *EP*₄^{-/-} neonates. The ductus arteriosus, which connects the main pulmonary artery and the descending aorta, shunt the pulmonary blood flow to the aorta during the fetal period (16) and closes just after birth in accordance with the start of respiration. In fact, PGE₂ relaxes via the EP₄ receptor the ductus arteriosus (17), in which the mRNA was abundantly expressed (15). Moreover, less than 5% of the *EP*₄^{-/-} neonates, those which survived and grew normally, had closed ductus arteriosus. These results suggest that left-sided heart failure caused by patent ductus arteriosus may be a major cause of neonatal death of *EP*₄^{-/-} mice. However, this patency of ductus arteriosus in *EP*₄^{-/-} neonates did not coincide with the relaxant actions mediated by the EP₄. The reason for this discrepancy is unknown and remains an interesting issue to be clarified.

Among the prostanoids produced by osteoblasts, PGE₂ is a major product and its synthesis is regulated by several cytokines. While PGE₂ primarily stimulates bone resorption in vitro, it stimulates both bone formation and resorption in vivo (18–20). Miyaura et al. and Sakuma et al. recently examined which subtypes of the EPs participate in this bone resorption to PGE₂ using mice lacking each of these subtypes (21, 22). PGE₂ concentration-dependently released Ca²⁺ into the medium of calvarial or long born cultures and induced osteoclast formation detected by staining for tartrate-resistant acid phosphatase. This bone-resorbing activity of PGE₂ was deficient specifically in cultures from *EP*₄^{-/-} mice, suggesting the mediation of this action by the EP₄. However, the roles of PGE₂ in both bone resorption and formation in vivo have not been fully elucidated; they are expected to be clarified in the near future using mice lacking each of the EP subtypes.

Roles of PGE₂ in fever generation and bicarbonate secretion in the duodenum

Fever is elicited by exogenous pyrogens such as lipopolysaccharide (LPS) and by non-infectious inflammatory insults. Both stimulate the production of inflammatory cytokines, which work as endogenous pyrogens acting on the brain (23). These cytokines include interleukin (IL)-1β, IL-6, IL-8, TNFα and macrophage inflammatory protein (MIP)-1β. Because aspirin-like drugs suppress fever, prostanoids have been implicated in fever generation (24). Among the prostanoids, PGE₂ was proposed as a central mediator of fever (25), but this has been much debated (23, 26–29). Moreover, the receptor subtype that mediates this action of PGE₂ has not been determined, although some investigators suggested the participation of the EP₁ using SC19220, an EP₁ antagonist, as a tool, which, however, was revealed not to be able to discriminate the four subtypes of the EP receptor of rodents (30). To address these issues, mice lacking each subtype of EPs were produced

(31). While PGE₂, when injected intracerebroventricularly, induced a febrile response in wild-type, *EP₁^{-/-}*, *EP₂^{-/-}* and *EP₄^{-/-}* mice all to a similar extent, *EP₃^{-/-}* mice failed to respond to PGE₂. *EP₃^{-/-}* mice also failed to respond to IL-1 β injected intravenously or intracerebroventricularly, indicating that EP₃ mediates the IL-1 β -Induced febrile response irrespective of the route of administration of IL-1 β . Fever generated by LPS, an exogenous pyrogen, cannot be accounted for by the action of IL-1 β alone (32, 33). For example, LPS induces the production of other endogenous pyrogens, including MIP-1 β and IL-8, which were suggested to induce fever in a prostaglandin-independent manner (34, 35). Therefore, attempts were made to determine whether the EP₃ also contributes to LPS-induced fever. The responsiveness of peritoneal macrophage to LPS was examined first by determining the production of IL-1 β and IL-6 because the prostanoids were reported to participate in the regulation of cytokine production of macrophages. Macrophages from *EP₃^{-/-}* mice produced the two cytokines in amounts similar to those observed with macrophages from the wild-type mice, indicating that the initial step of the response to LPS may not be impaired in *EP₃^{-/-}* mice. The febrile response to LPS was then examined. LPS injected intravenously induced a fever in wild-type mice, whereas it failed to induce a fever in *EP₃^{-/-}* mice, suggesting that the EP₃ is essential in the febrile response to LPS. It was also confirmed that *EP₃^{-/-}* mice show a normal febrile response when subjected to a restraint stress, suggesting that these mice maintain the efferent pathway to fever generation intact.

In the gastrointestinal tract, PGE₂ is a major prostanoid and shows a variety of actions (36). Among these actions, duodenal bicarbonate secretion is essential for maintaining mucosal integrity, because secreted bicarbonate protects the mucosa from acid-induced injury. While bicarbonate secretion is under control of neuronal regulation, endogenous PGE₂ produced by acid stimulation plays an important role in local maintenance of the surface pH gradient (37–39). However, physiological roles of PGE₂ in duodenal bicarbonate secretion and the receptor subtype(s) mediating the effect of PGE₂ have not been determined. Takeuchi et al. recently addressed this issue using *EP₁^{-/-}* and *EP₃^{-/-}* mice (40); duodenal bicarbonate secretion increased in response to mucosal acidification to a similar extent in wild-type and *EP₁^{-/-}* mice, although the duodenal mucosa of *EP₃^{-/-}* mice failed to respond at all to the stimulus. Taken together with the result that indomethacin completely suppressed the response in wild-type mice, PGE₂ would appear to play a major role via the EP₃ receptor in acid-induced bicarbonate secretion. In accordance with this result, acid-induced mucosal injury was markedly augmented in *EP₃^{-/-}* mice compared with that in wild-type mice and was almost similar to that in wild-type mice

pretreated with indomethacin, suggesting an important protective role of PGE₂ in acid-induced mucosal injury.

Roles of PGE₂ in reproduction and salt-sensitive hypertension

Prostanoids are implicated in various aspects of reproduction, including ovulation, fertilization, implantation, decidualization and parturition. For example, PGE₂ and PGF_{2 α} were reported to participate in luteinizing hormone-induced ovulation (41), and PGF_{2 α} is a potent luteolytic agent as described above. Moreover, mice lacking the cyclooxygenase-2 showed multiple reproductive failures in early pregnancy (42, 43), and mice lacking cytosolic phospholipase A₂ showed abnormal parturition similar to that found in *FP^{-/-}* mice (44). Female *EP₂^{-/-}* mice have reduced litter size (45–47). Hizaki et al. analyzed the mechanism of this reproductive failure in detail (45). The average number of embryos at day 19 of pregnancy in *EP₂^{-/-}* mice was 1.5, whereas that in wild-type mice was 7.1. There was no abnormality of implantation in *EP₂^{-/-}* mice, when examined by intrauterine transfer of wild-type blastocysts. However, *EP₂^{-/-}* females had slightly impaired ovulation and severely impaired fertilization in both natural ovulation and super-ovulation. Cumulus cells, which surround the oocytes, start to synthesize hyaluronic acid and to expand when triggered by the preovulatory surge of gonadotropins (48). This cumulus expansion facilitates ovulation through the ruptured follicle wall, capture of cumulus-oocyte complex by oviductal fimbria, and fertilization. In cumuli oophori from wild-type females, PGE₂, FSH and dibutyl cAMP elicited expansion in vitro. However, in cumuli oophori from *EP₂^{-/-}* females, only PGE₂ failed to elicit expansion. Moreover, abortive cumulus expansion was found in *EP₂^{-/-}* females in vivo. These results demonstrated that PGE₂ via the EP₂ contributes to cumulus expansion and that this contribution was indispensable for successful fertilization in the oviduct, where cumulus-oocyte complexes were already free from the influence of FSH.

Vascular responsiveness and blood pressure of *EP₂^{-/-}* mice was examined (46). Bolus administration of PGE₂ produced a transient hypotensive effect in wild-type mice, whereas it elicited a transient hypertensive response in *EP₂^{-/-}* mice, suggesting that the vasodilatory action of PGE₂ was mediated by the EP₂ and that the hypertensive response in *EP₂^{-/-}* mice may be induced by unopposed hypertensive actions mediated by the EP₁ and/or EP₃. While baseline blood pressure in *EP₂^{-/-}* mice was slightly higher only in females compared with that in wild-type females, marked elevation of systolic blood pressure was observed in *EP₂^{-/-}* mice after they were fed the high-salt diet. Systolic blood pressure did not change in wild-type mice when fed the high-salt diet. Urinary PGE₂ production

was increased within 2 days of beginning the high-salt diet to a similar extent in wild-type and $EP_2^{-/-}$ mice, suggesting that the high-salt diet stimulates the production of PGE_2 in the body. These results show that unopposed vasoconstriction via the EP_1 and/or EP_3 receptor in $EP_2^{-/-}$ mice could contribute to the observed hypertension, particularly when PGE_2 production was increased with a high-salt diet.

Roles of PGD_2 in allergic asthma

PGD_2 is released in large amounts by activated mast cells in response to antigen challenge (49) and has been proposed as a marker of mast cell activation in asthma (50). To clarify the role of PGD_2 in allergic asthma, Matsuoka et al. disrupted the gene encoding the DP (51). Mice were sensitized with intraperitoneal injections of ovalbumin followed by exposures to aerosolized ovalbumin. The serum concentrations of both total and ovalbumin-specific IgE were markedly increased in response to the antigen challenge to a similar extent in wild-type and $DP^{-/-}$ mice. In wild-type mice, total cell number in BAL fluid increased markedly compared with that of saline-treated control mice (22.2×10^5 versus 2.5×10^5), and the cells consisted of eosinophils (approx. 80%), lymphocytes (approx. 10%) and macrophages (approx. 10%) after the sensitization. However, in $DP^{-/-}$ mice, only marginal increases in the numbers of eosinophils and lymphocytes were observed, suggesting the failure in chemoattraction of these cells. Moreover, airway hyperreactivity to acetylcholine was induced by the sensitization in wild-type mice, whereas it was not induced in $DP^{-/-}$ mice. On the other hand, Th2 cytokines play an essential role in the pathogenesis of allergic asthma (52, 53). While, in wild-type mice, antigen challenge induced marked increases in the concentrations of Th2 cytokines such as IL-4, IL-5 and IL-13 in BAL fluid, these increases were significantly lower in $DP^{-/-}$ mice compared with those in wild-type mice. In contrast, no difference was observed in the increase in the concentration of interferon- γ , a Th1 cytokine, between wild-type and $DP^{-/-}$ mice. In accordance with these findings, Th2 cytokine-responsive cells, lymphocytes and eosinophils, extensively infiltrated in the bronchial submucosa and around the blood vessels of the lungs in antigen-challenged wild-type mice, and little cell infiltration was observed in the lungs of antigen-challenged $DP^{-/-}$ mice. Immunohistochemical examination using a specific antibody to the DP revealed the expression of the DP in the cells of bronchioles and alveoli in wild-type mice, which was markedly up-regulated by airway exposure to the antigen. Immunoelectron microscopy identified the cell types expressing the DP, which mainly included ciliated and non-ciliated epithelial cells in the bronchioles and type II alveolar epithelial cells. These results suggest that PGD_2 produced in response to allergic challenge acts on the DP to stimulate the produc-

tion of cytokines and chemokines, which lead to the recruitment of lymphocytes to the site of antigen challenge.

Roles of PGE_2 in colon carcinogenesis

Epidemiological studies have revealed a significant decrease in the death rates from colon cancer in individuals who have taken aspirin for prolonged periods (54). Non-steroidal anti-inflammatory drugs (NSAIDs) also inhibited chemically induced colon carcinogenesis (55), and they were found effective for the treatment of patients with familial adenomatous polyposis (56). While mutations in the APC gene were found in cancer cells from more than 80% of patients with sporadic colon cancer, disruption of the COX-2 gene in APC knockout mice markedly reduced the number and size of intestinal polyps (57), suggesting that prostanoids formed by the action of COX-2 participate in colon carcinogenesis. Watanabe et al. tested azoxymethane-induced colon carcinogenesis in $EP_1^{-/-}$ and $EP_3^{-/-}$ mice (58). The number of azoxymethane-induced aberrant crypt foci (ACF) in the colon of $EP_1^{-/-}$ mice decreased by approx. 40% relative to that for wild-type mice. In contrast, there was no such difference between $EP_3^{-/-}$ and wild-type mice. They further examined the effect of ONO-8711, a selective EP_1 antagonist, on colon carcinogenesis and found that it reduced by approx. 30% the number of ACF developed in the colon of azoxymethane-treated wild-type mice. ONO-8711 also reduced the number of intestinal polyps of Min mice by approx. 40%. The suppression potential of ONO-8711 is comparable to that of NSAIDs and COX-2 inhibitors on azoxymethane-induced ACF formation and intestinal polyp formation in Min mice. These results suggest that PGE_2 via the EP_1 mediates carcinogenic changes in the colon, and that selective EP_1 antagonists may be useful as chemopreventive agents for colon cancer.

Roles of TXA_2 in hemostasis and immunity

TXA_2 is well known as a potent stimulator of platelets and as a strong constrictor of vasculature. As is expected, $TP^{-/-}$ mice showed remarkably prolonged bleeding time, showing an essential role of TXA_2 in hemostasis (59). Some investigators have reported that the TP in smooth muscles cells of blood vessel has pharmacologically different characteristics from that of the TP in platelets. However, both blood vessel and platelets from the $TP^{-/-}$ mice failed to respond to U46619, a TP agonist, suggesting that the same products from the single known TP gene are expressed in both tissues. On the other hand, the TP was reported to be abundantly expressed on the T cells in the thymus and spleen, and TXA_2 was suggested to participate in the regulation of T cell functions (60). This role of TXA_2 will be clarified in the near future using mice lacking the TP.

Table 1. Roles of prostanoids revealed by studies using mice lacking specific prostanoid receptors

Prostanoids	Receptors	Roles	Reference Nos.
PGD ₂	DP	A mediator of allergic asthma	(51)
PGE ₂	EP ₁	Augmentation of colon carcinogenesis	(58)
	EP ₂	Ovulation and fertilization	(45, 46)
		Salt-sensitive hypertension	(46, 47)
	EP ₃	A mediator of febrile responses to pyrogens	(31)
		Acid-induced bicarbonate secretion in the duodenum	(38)
		Urinary concentration	(61)
	EP ₄	Closure of ductus arteriosus	(14, 15)
		Bone resorption	(21, 22)
PGF _{2α}	FP	An essential inducer of labor	(9)
PGI ₂	IP	Antithrombotic function, a mediator of inflammation	(7)
TXA ₂	TP	Hemostasis	(59)

Conclusions

Several important physiological and pathophysiological roles of prostanoids have been revealed by studies using mice lacking specific prostanoid receptors as summarized in Table 1. However, a number of known actions of prostanoids have still not been fully elucidated, especially regarding their roles in vivo. As presented in this article, knock-out mouse studies would contribute further to clarify these and any yet unknown roles of prostanoids and may lead to the development of novel drugs that could selectively regulate each function of the prostanoids.

Acknowledgments

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science, Sports and Culture of Japan and by the Research Grant for Cardiovascular Diseases (11C-1) from the Ministry of Health and Welfare of Japan. This work was also supported by grants from the Ono Medical Research Foundation, the Takeda Science Foundation, the Smoking Research Foundation and the Suhara Memorial Foundation.

REFERENCES

- Coleman RA, Kennedy I, Humphrey PPA, Bunce K and Lumley P: Prostanoids and their receptors. *In* Comprehensive Medicinal Chemistry, Vol 3, Membranes & Receptors, Edited by Emmett JC, pp 643–714, Pergamon Press, Oxford (1990)
- Coleman RA, Grix SP, Head SA, Louttit JB, Mallett A and Sheldrick RLG: A novel inhibitory receptor in piglet saphenous vein. *Prostaglandins* **47**, 151–168 (1994)
- Ushikubi F, Hirata M and Narumiya S: Molecular biology of prostanoid receptors: An overview. *J Lipid Mediat* **12**, 343–359 (1995)
- Narumiya S, Sugimoto Y and Ushikubi F: Prostanoid receptors: structures, properties and functions. *Physiol Rev* **79**, 1193–1226 (1999)
- Davies P, Bailey PJ, Goldenberg MM and Ford-Hutchinson AW: The role of arachidonic acid oxygenation products in pain and inflammation. *Annu Rev Immunol* **2**, 335–357 (1984)
- Bley KR, Hunter JC, Eglen RM and Smith JAM: The role of IP prostanoid receptors in inflammatory pain. *Trends Pharmacol Sci* **19**, 141–147 (1998)
- Murata T, Ushikubi F, Matsuoka T, Hirata M, Yamazaki A, Sugimoto Y, Ichikawa A, Aze Y, Tanaka T, Yoshida N, Ueno A, Oh-ishi S and Narumiya S: Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. *Nature* **388**, 678–682 (1997)
- Horton EW and Poyser NL: Uterine luteolytic hormone: a physiological role for prostaglandin F_{2α}. *Physiol Rev* **56**, 595–651 (1976)
- Sugimoto Y, Yamasaki A, Segi E, Tsuboi K, Aze Y, Nishimura T, Oida H, Yoshida N, Tanaka T, Katsuyama M, Hasumoto K, Murata T, Hirata M, Ushikubi F, Negishi M, Ichikawa A and Narumiya S: Failure of parturition in mice lacking the prostaglandin F receptor. *Science* **277**, 681–683 (1997)
- Soloff MS, Alexandrova M and Fernstrom MJ: Oxytocin receptors: triggers for parturition and lactation? *Science* **204**, 1313–1315 (1979)
- Kimura T, Tanizawa O, Mori K, Brownstein MJ and Okayama H: Structure and expression of a human oxytocin receptor. *Nature* **356**, 526–529 (1992)
- Thorburn GD and Challis JR: Endocrine control of parturition. *Physiol Rev* **59**, 863–918 (1979)
- Fuchs AR, Periyasamy S, Alexandrova M and Soloff MS: Correlation between oxytocin receptor concentration and responsiveness to oxytocin in pregnant rat myometrium: effects of ovarian steroids. *Endocrinology* **113**, 742–749 (1983)
- Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, Anderson PA, Malouf NN and Koller BH: The prostaglandin receptor EP₄ triggers remodelling of the cardiovascular system at birth. *Nature* **390**, 78–81 (1997)
- Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, Nishimura T, Murata T, Matsuoka T, Ushikubi F, Fukumoto M, Tanaka T, Yoshida N and Narumiya S: Patent ductus arteriosus and neonatal death in prostaglandin receptor EP₄-deficient mice. *Biochem Biophys Res Commun* **246**, 7–12 (1998)
- Heymann MA and Rudolph AM: Control of the ductus arteriosus. *Physiol Rev* **55**, 62–78 (1975)
- Smith GC, Coleman RA and McGrath JC: Characterization of dilator prostanoid receptors in the fetal rabbit ductus arteriosus. *J Pharmacol Exp Ther* **271**, 390–396 (1994)
- Suda T, Takahashi N and Martin TJ: Modulation of osteoclast differentiation. *Endocr Rev* **13**, 66–80 (1992)
- Raisz LG, Vanderhoek JY, Simmons HA, Kream BE and

- Nicolaou KC: Prostaglandin synthesis by fetal rat bone in vitro: evidence for a role of prostacyclin. *Prostaglandins* **17**, 905–914 (1979)
- 20 Sato K, Fujii Y, Kasono K, Saji M, Tsushima T and Shizume K: Stimulation of prostaglandin E₂ and bone resorption by recombinant human interleukin 1 alpha in fetal mouse bones. *Biochem Biophys Res Commun* **138**, 618–624 (1986)
 - 21 Miyaura C, Inada M, Suzawa T, Sugimoto Y, Ushikubi F, Ichikawa A, Narumiya S and Suda T: Impaired bone resorption to prostaglandin E₂ in prostaglandin E receptor EP4-knockout mice. *J Biol Chem* **275**, 19819–19823 (2000)
 - 22 Sakuma Y, Tanaka K, Suda M, Yasoda A, Natsui K, Tanaka I, Ushikubi F, Narumiya S, Segi E, Sugimoto Y, Ichikawa A and Nakao K: Crucial involvement of the EP4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. *J Bone Miner Res* **15**, 218–227 (2000)
 - 23 Kluger MJ: Fever: role of pyrogens and cryogens. *Physiol Rev* **71**, 93–127 (1991)
 - 24 Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. *Nature New Biol* **231**, 232–235 (1971)
 - 25 Milton AS and Wendlandt S: A possible role for prostaglandin E₁ as a modulator for temperature regulation in the central nervous system of the cat. *J Physiol (Lond)*, **207**, 76P–77P (1970)
 - 26 Stitt JT: Prostaglandin E as the neural mediator of the febrile response. *Yale J Biol Med* **59**, 137–149 (1986)
 - 27 Mitchell D, Laburn HP, Cooper KE, Hellon RF, Cranston WI and Townsend Y: Is prostaglandin E the neural mediator of the febrile response? The case against a proven obligatory role. *Yale J Biol Med* **59**, 159–168 (1986)
 - 28 Milton AS: Thermoregulatory actions of eicosanoids in the central nervous system with particular regard to the pathogenesis of fever. *Ann NY Acad Sci* **559**, 392–410 (1989)
 - 29 Saper CB and Breder CD: The neurologic basis of fever. *N Engl J Med* **330**, 1880–1886 (1994)
 - 30 Kiriya M, Ushikubi F, Kobayashi T and Narumiya S: Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. *Br J Pharmacol* **122**, 217–224 (1997)
 - 31 Ushikubi F, Segi E, Sugimoto Y, Murata T, Matsuoka T, Kobayashi T, Hizaki H, Tuboi K, Katsuyama M, Ichikawa A, Tanaka T, Yoshida N and Narumiya S: Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP₃. *Nature* **395**, 281–284 (1998)
 - 32 Zheng, H, Fletcher D, Kozak W, Jiang M, Hofmann KJ, Conn CA, Soszynski D, Grabiec C, Trumbauer ME, Shaw A, Kostura MJ, Stevens K, Rosen H, North RJ, Chen HY, Tocci MJ, Kluger MJ and Van der Ploeg LHT: Resistance to fever induction and impaired acute-phase response in interleukin-1 β -deficient mice. *Immunity* **3**, 9–19 (1995)
 - 33 Kozak W, Zheng H, Conn CA, Soszynski D, van der Ploeg LH and Kluger MJ: Thermal and behavioral effects of lipopolysaccharide and influenza in interleukin-1 β -deficient mice. *Am J Physiol* **269**, R969–R977 (1995)
 - 34 Davatellis G, Wolpe SD, Sherry B, Dayer JM, Chicheportiche R and Cerami A: Macrophage inflammatory protein-1: a prostaglandin-independent endogenous pyrogen. *Science* **243**, 1066–1068 (1989)
 - 35 Zampronio AR, Souza GE, Silva CA, Cunha FQ and Ferreira SH: Interleukin-8 induces fever by a prostaglandin-independent mechanism. *Am J Physiol* **266**, R1670–R1674 (1994)
 - 36 Hawkey CJ and Rampton DS: Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? *Gastroenterology* **89**, 1162–1188 (1985)
 - 37 Heylings JR, Garner A and Flemstrom G: Regulation of gastroduodenal HCO₃⁻ transport by luminal acid in the frog in vitro. *Am J Physiol* **246**, G235–G246 (1984)
 - 38 Takeuchi K, Furukawa O, Tanaka H and Okabe S: A new model of duodenal ulcers induced in rats by indomethacin plus histamine. *Gastroenterology* **90**, 636–645 (1986)
 - 39 Hogan DL, Yao B, Steinbach JH and Isenberg JI: The enteric nervous system modulates mammalian duodenal mucosal bicarbonate secretion. *Gastroenterology* **105**, 410–417 (1993)
 - 40 Takeuchi K, Kawa H, Kato S, Furukawa O, Araki H, Sugimoto Y, Ichikawa A, Ushikubi F and Narumiya S: Impaired duodenal bicarbonate secretion and mucosal integrity in mice lacking prostaglandin E-receptor subtype EP₃. *Gastroenterology* **117**, 1128–1135 (1999)
 - 41 Murdoch WJ, Hansen TR and McPherson LA: Role of eicosanoids in vertebrate ovulation. *Prostaglandins* **46**, 85–115 (1993)
 - 42 Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA and Searle AG: Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. *Nature* **378**, 406–409 (1995)
 - 43 Lim H, Paria BC, Das SK, Dinchuk JE, Langenbach R, Trzaskos JM and Dey SK: Multiple female reproductive failures in cyclooxygenase 2-deficient mice. *Cell* **91**, 197–208 (1997)
 - 44 Uozumi N, Kume K, Nagase T, Nakatani N, Ishii S, Tashiro F, Komagata Y, Maki K, Ikuta K, Ouchi Y, Miyazaki J and Shimizu T: Role of cytosolic phospholipase A₂ in allergic response and parturition. *Nature* **390**, 618–622 (1997)
 - 45 Hizaki H, Segi E, Sugimoto Y, Hirose M, Saji T, Ushikubi F, Matsuoka T, Noda Y, Tanaka T, Yoshida N, Narumiya S and Ichikawa A: Abortive expansion of the cumulus and impaired fertility in mice lacking the prostaglandin E receptor subtype EP₂. *Proc Natl Acad Sci USA* **96**, 10501–10506 (1999)
 - 46 Kennedy CR, Zhang Y, Brandon S, Guan Y, Coffee K, Funk CD, Magnuson MA, Oates JA, Breyer MD and Breyer RM: Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP₂ receptor. *Nat Med* **5**, 217–220 (1999)
 - 47 Tilley SL, Audoly LP, Hicks EH, Kim HS, Flannery PJ, Coffman TM and Koller BH: Reproductive failure and reduced blood pressure in mice lacking the EP₂ prostaglandin E₂ receptor. *J Clin Invest* **103**, 1539–1545 (1999)
 - 48 Eppig JJ: FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatory follicles. *Nature* **281**, 483–484 (1979)
 - 49 Lewis RA and Austen KF: Mediation of local homeostasis and inflammation by leukotrienes and other mast cell-dependent compounds. *Nature* **293**, 103–108 (1981)
 - 50 Murray JJ, Tonnel AB, Brash AR, Roberts LJ, Gosset P, Workman R, Capron A and Oates JA: Release of prostaglandin D₂ into human airways during acute antigen challenge. *N Engl J Med* **315**, 800–804 (1986)
 - 51 Matsuoka T, Hirata M, Tanaka H, Takahashi Y, Murata T, Kabashima K, Sugimoto Y, Kobayashi T, Ushikubi F, Aze Y, Eguchi N, Urade Y, Yoshida N, Kimura K, Mizoguchi A, Honda Y, Nagai H and Narumiya S: Prostaglandin D₂ as a mediator of

- allergic asthma. *Science* **287**, 2013–2017 (2000)
- 52 Foster PS, Hogan SP, Ramsay AJ, Matthaei KI and Young IG: Interleukin 5 deficiency abolishes eosinophilia, airways hyper-reactivity, and lung damage in a mouse asthma model. *J Exp Med* **183**, 195–201 (1996)
 - 53 Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, Sheppard D, Mohrs M, Donaldson DD, Locksley RM and Corry DB: Requirement for IL-13 independently of IL-4 in experimental asthma. *Science* **282**, 2261–2263 (1998)
 - 54 Thun MJ, Namboodiri MM and Heath CW Jr: Aspirin use and reduced risk of fatal colon cancer. *N Engl J Med* **325**, 1593–1596 (1991)
 - 55 Reddy BS, Tokumo K, Kulkarni N, Aligia C and Kelloff G: Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. *Carcinogenesis* **13**, 1019–1023 (1992)
 - 56 Giardiello FM, Hamilton SR, Krush AJ, Piantadosi S, Hyland LM, Celano P, Booker SV, Robinson CR and Offerhaus GJ: Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. *N Engl J Med* **328**, 1313–1316 (1993)
 - 57 Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF and Taketo MM: Suppression of intestinal polyposis in *Apc*^{Δ716} knockout mice by inhibition of cyclooxygenase 2 (COX-2). *Cell* **87**, 803–809 (1996)
 - 58 Watanabe K, Kawamori T, Nakatsugi S, Ohta T, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Ushikubi F, Narumiya S, Sugimura T and Wakabayashi K: Role of the prostaglandin E receptor subtype EP₁ in colon carcinogenesis. *Cancer Res* **59**, 5093–5096 (1999)
 - 59 Thomas DW, Mannon RB, Mannon PJ, Latour A, Oliver JA, Hoffman M, Smithies O, Koller BH and Coffman TM: Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A₂. *J Clin Invest* **102**, 1994–2001 (1998)
 - 60 Ushikubi F, Aiba Y, Nakamura K, Namba T, Hirata M, Mazda O, Katsura Y and Narumiya S: Thromboxane A₂ receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis. *J Exp Med* **178**, 1825–1830 (1993)
 - 61 Fleming EF, Athirakul K, Oliverio MI, Key M, Goulet J, Koller BH and Coffman TM: Urinary concentrating function in mice lacking EP₃ receptors for prostaglandin E₂. *Am J Physiol* **275**, F955–F961 (1998)